Brief: Neurosense Therapeutics Granted Key U.S. Patent For Novel Primec Formulation

Neurosense Therapeutics

24/09/2024 14:28

Sept 24 (Reuters) - Neurosense Therapeutics Ltd
 NRSN.O :
    * NEUROSENSE THERAPEUTICS GRANTED KEY U.S. PATENT FOR NOVEL
PRIMEC
FORMULATION, ITS LEAD ASSET FOR ALS AND ALZHEIMER'S
    * NEUROSENSE THERAPEUTICS LTD: PATENT PROTECTION EXTENDS
THROUGH
2042, ADDING 4 ADDITIONAL YEARS TO PRIMEC'S IP UMBRELLA

Source text for Eikon:  ID:nPn4J70bPa 
Further company coverage:  NRSN.O 

 ((Reuters.Briefs@thomsonreuters.com;))